Published in Clin Exp Immunol on November 01, 1971
Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. Infect Immun (1993) 2.08
Variability in expression of a cell surface determinant on Candida albicans as evidenced by an agglutinating monoclonal antibody. Infect Immun (1984) 2.07
Specific inhibition of in vitro Candida-induced lymphocyte proliferation by polysaccharidic antigens present in the serum of patients with chronic mucocutaneous candidiasis. J Clin Invest (1978) 2.03
Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev (1996) 1.90
Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis. Infect Immun (1993) 1.84
Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis. Infect Immun (1994) 1.68
Immunity to Candida albicans. Microbiol Rev (1980) 1.66
Regulation of delayed hypersensitivity. Failure to transfer delayed hypersensitivity to desensitized guinea pigs. J Exp Med (1973) 1.66
Effect of transfer factor on lymphocyte function in anergic patients. J Clin Invest (1972) 1.52
Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity. Infect Immun (1995) 1.48
Candida mannan: chemistry, suppression of cell-mediated immunity, and possible mechanisms of action. Clin Microbiol Rev (1991) 1.32
Characterization of Candida albicans mannan-induced, mannan-specific delayed hypersensitivity suppressor cells. Infect Immun (1990) 1.31
Precipitins to Candida albicans in chronic mucocutaneous candidiasis studied by crossed immunoelectrophoresis with intermediate gel. Correlation with clinical and immunological findings. Clin Exp Immunol (1974) 1.28
Mannan as an antigen in cell-mediated immunity (CMI) assays and as a modulator of mannan-specific CMI. Infect Immun (1989) 1.19
An immune defect causing dominant chronic mucocutaneous candidiasis and thyroid disease maps to chromosome 2p in a single family. Am J Hum Genet (2001) 1.18
Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans. Antimicrob Agents Chemother (1985) 1.18
In vivo suppression of delayed hypersensitivity: prolongation of desensitization in guinea pigs. J Exp Med (1975) 1.02
Immunohistochemical evaluation of T cells in oral lesions from human immunodeficiency virus-positive persons with oropharyngeal candidiasis. Infect Immun (2003) 0.93
Use of cellular depletion analysis to examine circulation of immune effector function between the vagina and the periphery. Infect Immun (1997) 0.93
Effect of delayed-type hypersensitivity reaction and transferred lymphokine on the resistance of mice to Salmonella typhimurium infection. Infect Immun (1983) 0.87
Characterization of the cellular immune function of patients with chronic mucocutaneous candidiasis. Clin Exp Immunol (2001) 0.85
Radioimmunoassays that use 125I-labeled protein A for determination of Histoplasma capsulatum-specific immunoglobulin G, A, and M class antibodies in histoplasmosis. J Clin Microbiol (1981) 0.83
A further characterization of Candida albicans-induced suppressor B-cell activity. Immunology (1989) 0.81
One-way stimulation in mixed leukocyte cultures. Science (1966) 6.62
Infection and nitroblue-tetrazolium reduction by neutrophils. A diagnostic acid. Lancet (1968) 5.30
Transfer factor. Adv Immunol (1969) 2.76
Immunological observations in chronic mucocutaneous candidiasis. Lancet (1969) 2.29
Chronic mucocutaneous candidiasis, deficiency of delayed hypersensitivity, and selective local antibody defect. Lancet (1967) 2.19
Spontaneous in vitro reduction of nitroblue tetrazolium by neutrophils of adult patients with bacterial infection. N Engl J Med (1971) 2.16
Studies of PPLO infection. V. Inhibition of lymphocyte mitosis and antibody formation by mycoplasmal extracts. J Exp Med (1969) 1.86
The susceptibility to moniliasis in children with endocrine hypofunction. Trans Assoc Am Physicians (1967) 1.13
Extensive cutaneous moniliasis. Treatment with amphotericin B. Am J Dis Child (1961) 0.89
Experimental allergic encephalomyelitis and autoimmune disease. Adv Immunol (1966) 3.74
Spontaneous in vitro reduction of nitroblue tetrazolium by neutrophils of adult patients with bacterial infection. N Engl J Med (1971) 2.16
Vancomycin-streptomycin synergism in enterococcal endocarditis. JAMA (1973) 1.99
Counterimmunoelectrophoresis for rapid diagnosis of meningitis due to Diplococcus pneumoniae. J Infect Dis (1973) 1.86
Experimental allergic encephalomyelitis: role of fibrin deposition in immunopathogenesis of inflammation in rats. Fed Proc (1976) 1.62
Localization of C-reactive protein in inflammatory lesions of experimental allergic encephalomyelitis. Clin Exp Immunol (1981) 1.48
In vitro demonstration of cellular sensitivity in allergic encephalomyelitis. J Exp Med (1965) 1.22
Current perspectives of neuroimmunologic disease: multiple sclerosis and experimental allergic encephalomyelitis (1,2). Clin Immunol Rev (1983) 1.16
Rapid induction of experimental allergic thyroiditis in rats sensitized to thyroid-adjuvant and pertussis vaccine. J Immunol (1968) 1.14
Cyclophosphamide: effect on experimental allergic encephalomyelitis in Lewis rats. Science (1969) 1.08
Ploidy, proliferative activity and estrogen receptor content in human breast cancer. Cytometry (1982) 1.07
Multiple sclerosis: an immunologic reassessment. J Chronic Dis (1973) 1.06
Induction of experimental allergic encephalomyelitis in Lewis rats. Int Arch Allergy Appl Immunol (1970) 1.03
Immune processes and infectious factors in central nervous system disease. Annu Rev Med (1969) 1.02
Intact B-cell activity is essential for complete expression of experimental allergic encephalomyelitis in Lewis rats. Cell Immunol (1982) 1.01
N.B.T. tests in a patient on steroids. Lancet (1971) 0.98
Hormonal therapy for metastatic male breast cancer. Arch Intern Med (1983) 0.97
Induction of experimental allergic encephalomyelitis in Lewis rats with purified synthetic peptides: delineation of antigenic determinants for encephalitogenicity, in vitro activation of cellular transfer, and proliferation of lymphocytes. Proc Natl Acad Sci U S A (1985) 0.96
Adjuvants, cell-mediated immune responses and autoimmune disease. J Reticuloendothel Soc (1973) 0.94
Cyclophosphamide inhibition of experimental allergic encephalomyelitis and cellular transfer of the disease in Lewis rats. J Immunol (1969) 0.94
In vitro effects of phytohemagglutinin and brain antigen on cell transfer of experimental autoimmune encephalomyelitis in Lewis rats. J Immunol (1968) 0.93
Erythromycin-resistant pneumococcal osteomyelitis. Am J Med (1970) 0.93
Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. J Clin Oncol (1991) 0.92
Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treat Rev (2011) 0.91
Role of the clotting system in the pathogenesis of neuroimmunologic disease. Fed Proc (1987) 0.90
Rheumatic carditis: in vitro responses of peripheral blood leukocytes to heart and streptococcal antigens. Arthritis Rheum (1973) 0.90
Immunosuppression and the Guillain-Barré syndrome. Arch Neurol (1970) 0.90
Complement-fixing antibrain antibodies and allergic encephalomyelitis. II. Further studies concerning their protective role. Ann N Y Acad Sci (1965) 0.90
The human tumor stem cell assay revisited. Int J Cell Cloning (1985) 0.89
Effect of indomethacin treatment upon actively-induced and transferred experimental allergic encephalomyelitis (EAE) in Lewis rats. Clin Exp Immunol (1982) 0.88
CSF carcinoembryonic antigen in meningeal carcinomatosis from breast cancer. JAMA (1980) 0.88
Experimental allergic encephalomyelitis in suckling Lewis rats: comparison with the disease in adult animals. Lab Invest (1977) 0.87
Cellular transfer of experimental allergic encephalomyelitis: altered disease pattern in irradiated recipient lewis rats. Cell Immunol (1975) 0.87
Cellular transfer of experimental allergic encephalomyelitis employing suckling and adult Lewis rats. J Clin Lab Immunol (1981) 0.87
Neurovascular permeability and fibrin deposition in the central neuraxis of Lewis rats with cell-transferred experimental allergic encephalomyelitis in relationship to clinical and histopathological features of the disease. J Neuroimmunol (1993) 0.87
Cyclophosphamide treatment of experimental allergic encephalomyelitis in Lewis rats. J Immunol (1971) 0.87
Induction of experimental allergic encephalomyelitis in suckling Lewis rats: role of age and type of sensitizing neuroantigen. J Immunol (1977) 0.86
Autoimmune diseases of myelin. Prog Clin Biol Res (1980) 0.85
Indomethacin augments in vitro proliferative responses of Lewis rat lymphocytes to myelin basic protein. Implications for experimental autoimmune encephalomyelitis. Cell Immunol (1989) 0.84
Cerebrospinal fluid and serum oligoclonal IgG bands in rabbits with experiment allergic encephalomyelitis. Neurochem Res (1981) 0.84
Endogenous myelin basic protein-serum factors (MBP-SFs) and anti-MBP antibodies in humans. Occurrence in sera of clinically well subjects and patients with multiple sclerosis. J Neurol Sci (1981) 0.83
Adjuvanticity of mycobacterial RNA and poly A:U for induction of experimental allergic encephalomyelitis in guinea pigs. J Immunol (1973) 0.83
Cyclophosphamide in exacerbations of multiple sclerosis. Therapeutic trial and a strategy for pilot drug studies. J Neurol Neurosurg Psychiatry (1975) 0.83
Cellular transfer of experimental allergic encephalomyelitis in Lewis rats: effects of different sensitization regimens on in vitro reactivity of donor spleen cells to concanavalin A. Cell Immunol (1981) 0.83
Estrogen receptor status in inflammatory breast carcinoma. J Surg Oncol (1982) 0.83
Molecular and cellular determinants of neuroimmunologic inflammatory disease. Fed Proc (1982) 0.83
Cyclosphosphamide inhibition of experimental allergic thyroiditis and thyroid antibody production in rats. J Immunol (1971) 0.83
Interleukin 1 and myelin basic protein synergistically augment adoptive transfer activity of lymphocytes mediating experimental autoimmune encephalomyelitis in Lewis rats. J Immunol (1987) 0.83
Studies of cyclophosphamide suppression of experimental allergic encephalomyelitis in Wistar rats. J Immunol (1969) 0.83
Myelin basic protein serum factor (MBP-SF) in adult Lewis rats: a method for detection and evidence that MBP-SF influences the appearance of antibody to MBP in animals developing experimental allergic encephalomyelitis. Immunochemistry (1978) 0.83
Occurrence and erythromycin susceptibility of penicillin-resistant Viridans streptococci in rheumatic fever patients on oral penicillin prophylaxis. Antimicrob Agents Chemother (Bethesda) (1968) 0.82
Role of macrophage-myelin basic protein interaction in the induction of experimental allergic encephalomyelitis in Lewis rats. J Immunol (1983) 0.82
Potentiation of experimental allergic encephalomyelitis in hamsters with persistent encephalitis due to measles virus. J Infect Dis (1979) 0.82
Myelin basic protein serum factor. An endogenous neuroantigen influencing development of experimental allergic encephalomyelitis in Lewis rats. J Exp Med (1978) 0.82
Cerebrospinal fluid beta-glucuronidase activity in rabbits with experimental allergic encephalomyelitis. Clin Exp Immunol (1970) 0.82
Antigen-specific inhibition of the adoptive transfer of experimental autoimmune encephalomyelitis in Lewis rats. J Neuroimmunol (1992) 0.81
Endogenous myelin basic protein-serum factors (MBP-SFs) in Lewis rats. Evidence for their heterogeneity and reactivity with anti-MBP antibodies of different affinities. J Neurol Sci (1981) 0.81
Microbial parasitism cross-reactive with host antigen: implications concerning loss of "self" tolerance and development of autoimmune disease. Recomb DNA Tech Bull (1981) 0.81
Thyroid disease following irradiation for benign conditions. Arch Surg (1977) 0.80
Urine beta-glucuronidase in renal injury. I. Enzyme assay conditions and response to mercuric chloride in rats. J Lab Clin Med (1969) 0.80
Specific cell binding using staphylococcal protein A magnetic microspheres. J Pharm Sci (1981) 0.80
MBP-SF, a prominent serum factor in suckling Lewis rats that additively inhibits the primary binding of myelin basic protein (MBP) to syngeneic anti-MBP antibodies. Immunochemistry (1978) 0.80
Reversal of experimental allergic thyroiditis in cyclophosphamide-treated rats. Clin Exp Immunol (1975) 0.80
The effect of antisera against rat immunoglobulins on cellular transfer of experimental allergic encephalomyelitiin Lewis rats. Clin Exp Immunol (1970) 0.80
Clonogenic in vitro growth and histologic grading of primary human breast tumors. Int J Cell Cloning (1985) 0.80
Experimental allergic encephalomyelitis (EAE) in mice selectively bred to produce high affinity (HA) or low affinity (LA) antibody responses. Immunology (1990) 0.80
Suppression of clinical signs of cell-transferred experimental allergic encephalomyelitis and altered cerebrovascular permeability in Lewis rats treated with a plasminogen activator inhibitor. Cell Immunol (1987) 0.80
Use of progressive pneumoperitoneum in the treatment of giant abdominal hernias. Am Surg (1978) 0.80
Neuroimmunologic disease: experimental and clinical aspects. Hosp Pract (1979) 0.79
Joseph E. Smadel Memorial Lecture: neuroimmunologic diseases of animals and humans. Rev Infect Dis (1980) 0.79
Immunologic determinants of experimental neurologic autoimmune disease and approaches to the multiple sclerosis problem. Trans Am Clin Climatol Assoc (1978) 0.79
Cyclophosphamide inhibition of experimental allergic encephalomyelitis in Wistar rats. Proc Soc Exp Biol Med (1967) 0.79
Urine beta-glucuronidase in renal injury. II. Excretion patterns in experimental staphylococcal pyelonephritis in rats. J Lab Clin Med (1969) 0.79
Phase I-II study of high-dose mitomycin with autologous bone marrow transplantation in refractory metastatic breast cancer. Cancer Treat Rep (1984) 0.79
Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trial. Mol Biother (1992) 0.79
Temporal dissociation of experimental allergic encephalomyelitis transfer activity and gamma globulin staining of lymphoid cells from sensitized Lewis rats. J Immunol (1970) 0.79
Immunosuppression and the Guillain-Barré syndrome. Neurology (1970) 0.78
Irradiation potentiation of cellular transfer of EAE: time course and locus of effect in irradiated recipient Lewis rats. Cell Immunol (1978) 0.78
Encephalitogenic and proliferative responses of Lewis rat lymphocytes distinguished by position 75- and 80-substituted peptides of myelin basic protein. J Immunol (1989) 0.78
Serum degradation of myelin basic protein with loss of encephalitogenic activity: evidence for an enzymatic process. Cell Immunol (1978) 0.78
LT/EAE and the MS quest. Going to the dogs and rats to study the patient. Cell Immunol (1983) 0.78
A marrow harvest procedure under local anesthesia. Exp Hematol (1995) 0.78
The N- and C-terminal boundaries of myelin basic protein determinants required for encephalitogenic and proliferative responses of Lewis rat T cells. J Neuroimmunol (1990) 0.78
Laser vaporization of genital condylomata in pregnancy. J Gynecol Surg (1990) 0.77
Neurovascular fibrinolytic activity in normal Lewis rats and rats with cell-transferred experimental allergic encephalomyelitis. J Neuroimmunol (1990) 0.77
Concordance and localization of maximal vascular permeability change and fibrin deposition in the central neuraxis of Lewis rats with cell-transferred experimental allergic encephalomyelitis. J Neuroimmunol (1992) 0.77
Potential cardiotoxicity with mitoxantrone. Cancer Treat Rep (1982) 0.77
Experimental allergic encephalomyelitis supernatant transfer activity (EAE-STA) in Lewis rats:immunobiologic and initial biochemical properties. J Immunol (1980) 0.77
Life-threatening infection. Choice of alternate drugs when penicillin cannot be given. JAMA (1969) 0.76
Clonotypic heterogeneity of Lewis rat T cells specific for the encephalitogenic 68-86 region of myelin basic protein. Cell Immunol (1989) 0.76
Transfer of experimental allergic encephalomyelitis in Lewis rats using supernates of incubated sensitized lymph node cells. J Exp Med (1977) 0.76
Magnetic microspheres as drug carriers: factors influencing localization at different anatomical sites in rats. Isr J Med Sci (1983) 0.76
Five-day continuous-infusion vinblastine in the treatment of breast cancer. Cancer (1985) 0.75
Distinct accessory cell requirements define two types of rat T cell hybridomas specific for unique determinants in the encephalitogenic 68-86 region of myelin basic protein. J Immunol (1990) 0.75
Neuroimmunologic diseases: effector cell responses and immunoregulatory mechanisms. Immunol Rev (1981) 0.75
The clotting system: gatekeeper of cerebrovascular permeability and monitor of clinical manifestations of neuroautoimmune disease. Trans Am Clin Climatol Assoc (1986) 0.75
Infectious and immune synergistic factors in tissue injury. Parallels between chronic obstructive respiratory disease and chronic pyelonephritis. Yale J Biol Med (1968) 0.75
Rickettsialpox. Bull N Y Acad Med (1966) 0.75
Rickettsialpox. Bull N Y Acad Med (1966) 0.75
Niridazole suppression of experimental allergic encephalomyelitis in Lewis rats. J Immunol (1977) 0.75